Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September

Key Points

• Citius Oncology, Inc. experienced a significant decrease in short interest of 55.2% in September, with current short interest totaling 135,800 shares.
• Several institutional investors increased their positions in Citius Oncology, with 70.52% of the stock now owned by hedge funds and other institutions.
• Research analysts have upgraded Citius Oncology's stock rating from "hold" to "buy," citing a target price of $6.00 based on increased confidence in the company.

Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 135,800 shares, a decline of 55.2% from the August 31st total of 303,400 shares. Currently, 1.2% of the shares of the company are short sold. Based on an average trading volume of 1,340,000 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 1,340,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.2% of the shares of the company are short sold.

Institutional Trading of Citius Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock worth $37,000 after purchasing an additional 8,411 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Citius Oncology in the 2nd quarter worth $465,000. Geode Capital Management LLC increased its holdings in shares of Citius Oncology by 179.0% in the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company's stock worth $249,000 after buying an additional 36,758 shares during the last quarter. Arkadios Wealth Advisors bought a new position in shares of Citius Oncology in the 2nd quarter worth $51,000. Finally, Citadel Advisors LLC bought a new position in shares of Citius Oncology in the 4th quarter worth $26,000. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CTOR shares. Maxim Group upgraded shares of Citius Oncology from a "hold" rating to a "buy" rating and set a $6.00 target price on the stock in a research note on Tuesday, September 23rd. Wall Street Zen upgraded shares of Citius Oncology to a "hold" rating in a research note on Saturday, July 26th. Finally, Citigroup upgraded shares of Citius Oncology from a "hold" rating to a "buy" rating in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $6.00.

Citius Oncology Stock Performance

NASDAQ CTOR traded up $0.01 on Friday, hitting $1.89. The stock had a trading volume of 55,318 shares, compared to its average volume of 1,117,681. Citius Oncology has a 52-week low of $0.55 and a 52-week high of $6.19. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.02 and a current ratio of 0.35. The firm has a 50-day moving average of $1.89 and a 200-day moving average of $1.61.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.